MBQ Pharma is an oncotherapy company, developing Rac and CDC42 inhibitors as tumor growth inhibitors and for the removal of pre-existing metastases. Candidates to inhibit these targets have been unsuccessfully sought over the past 20 years. The pipeline of compounds binding to these targets is led by MBQ-167, the compound with the first IC50 in the nanomolar range for binding to Rac and CDC42. This IC50 also makes this compound the best candidate to be developed as an oncology therapy. MBQ-167 is the lead compound of MBQ Pharma and the first nanomolar IC50 inhibitor for Rac/CDC42. Its IND package is being completed after a successful pre-IND meeting with the FDA. The IC50 of MBQ-167 makes this compound the best candidate to be developed as a therapy for advanced metastatic cancer patients. MBQ-167 is the result of 23 years of research by the MBQ Pharma founding team at the University of Puerto Rico. Preclinical development of MBQ-167 is funded from a $2.8 M MBQ Pharma seed round.